¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cellular immunity deficiency syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® battered child syndrome ÇÑ±Û ¸Å¸Â´Â ¾ÆÀÌ ÁõÈıº
¼³¸í   
  ¿µÀ¯¾Æ³ª ¼Ò¾Æ°¡ ºÎ¸ð µîÀÇ º¸À°ÀÚ³ª ÇüÁ¦ÀڸŷκÎÅÍ ¹Ýº¹Çؼ­ ½ÅüÀûÀΠÇд븦 ¹Þ¾Æ ¹ß»ýÇϴ °¢Á¾ Áõ»çÀÇ ÃÑĪÀÌ´Ù. 1962³â ÄÍÇÁ(Kempe)¿¡ ÀÇÇØ ¸í¸íµÇ¾ú´Ù. »ó󸦠¹ÞÀº ½Ã±â°¡ ¼­·Î Â÷À̰¡ Àִ ¿Ü»óÀÌ ¸ö Àüü ¿©·¯ °÷¿¡¼­ °üÂûµÇ´Â °ÍÀ̠Ư¡ÀÌ´Ù. ÇǺÎÀÇ ¼Õ»ó°ú ¾ó·èÃâÇ÷, °æÁú¸·ÇÏ Ç÷Á¾, °ñÀý µîÀÌ ¸¹°í ±Ø´ÜÀûÀΠ°æ¿ì´Â ¿µ±¸Àû ³ú¼Õ»ó°ú Á×À½¿¡ À̸£´Â °æ¿ìµµ ÀÖ´Ù. Çд뵿±â´Â ÇÇÇØÀÚ ÀÔÀå¿¡¼­´Â À°Ã¼Àû-Á¤½ÅÀû ¹ßÀ°ºÎÀü, ½ÖµÕÀÌ, ±âÇü, ¹ãÁß¿¡ ¿ì´Â °Í, ¾ß´¢Áõ, Àå³­, ¹ÝÇ×Àû Åµµ µîÀÌ ÀÖÀ¸¸ç °¡ÇØÀÚ ÀÔÀå¿¡¼­´Â º¸À°ÀÚÀÇ ¾ÆÀÌ¿¡ ´ëÇÑ ¾ÖÁ¤°áÇ̰ú °úÀ× ±â´ë, À°¾Æ¿¡ ´ëÇÑ ¹«Áö, ÇüÁ¦Àڸſ¡ ´ëÇÑ ½Ã»ù, Á¤½Åº´, ½Å°æÁõ, Áö´ÉÀúÇÏ, ¾ËÄڿàÁßµ¶ µîÀÌ ÀÖ°í, ¶Ç »ýȰȯ°æÀÇ ÀÔÀå¿¡¼­´Â ºó°ï, ºÎºÎ ºÒÈ­, ÇÙ°¡Á·À̸鼭 »çȸÀûÀ¸·Î °í¸³µÈ °¡Á¤ µîÀ» µé ¼ö ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û »ç½º
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. 
  
  
¿µ¹® congenital rubella syndrome ÇÑ±Û ¼±ÃµÇ³ÁøÁõÈıº
¼³¸í   
  ÀӽűⰣ Áß¿¡ »ê¸ð°¡ Ç³Áø¿¡ °É¸®¸é À̠dzÁø ¹ÙÀÌ·¯½º´Â Å¹ÝÀ» ÅëÇØ¼­ Å¾ƿ¡°Ô Àü´ÞµÇ¾î¼­ Å¾ÆÀǠdzÁø°¨¿°À» ÀÏÀ¸Å²´Ù. ÀӽŠù 3°³¿ù µ¿¾È, Æ¯È÷ ÀӽŠù´Þ¿¡ Å¾ư¡ Ç³ÁøÀÇ °¨¿°À» ¹ÞÀ¸¸é, ½Å»ý¾Æ¿¡¼­ ¼±Ãµ±âÇü, Áï ´«¿¡¼­ ÃÐÁ¡À» Á¤È®È÷ ¸ÂÃß¾îÁִ ·»ÁîÀÇ ¿ªÇÒÀ» Çϴ ¼öÁ¤Ã¼ÀǠȥŹ(¹é³»Àå), ½ÉÀå±âÇü, ±Í¸Ó°Å¸® ¹× ½ÉÇÑ Áö´É¹Ú¾àÀ» µ¿¹ÝÇϴ ¼ÒµÎÁõ µîÀÌ ¹ß»ýÇϴ ¼ö°¡ ¸¹´Ù.
¿µ¹® carpal tunnel syndrome ÇÑ±Û ¼Õ¸ñ±¼ÁõÈıº
¼³¸í   
  ¼Õ¸ñ¿¡´Â ¾ÆÈ© °³ÀÇ ÈûÁÙ°ú ÇÑ °³ÀÇ ½Å°æÀÌ Åë°úÇϴ ±¼ÀÌ Àִµ¥ À̰÷À» ¼Õ¸ñ±¼À̶ó Çϰí, À̰÷À» Áö³ª´Â ½Å°æÀÌ ´­¸®¸é »õ±ú¼Õ°¡¶ôÀ» Á¦¿ÜÇÑ ³× ¼Õ°¡¶ôÀÌ ¾ÆÇÁ°í Àú¸° Áõ»óÀÌ´Ù. À̰ÍÀ» ¼Õ¸ñ±¼ÁõÈıºÀ̶ó ÇÑ´Ù. °Ë»ç ¹æ¹ýÀ¸·Î´Â ±ÙÀ° °Ë»ç¿Í ½Å°æÀü´Þ°Ë»ç°¡ ÀÖ´Ù. ½ÉÇÒ ¶§´Â ¾ÆÄ§À̳ª Àú³á¿¡ ¾ÆÆÄ¼­ ÀáÀ» ±ú°í ¼Õ¸ñ»Ó¸¸ ¾Æ´Ï¶ó ¾î±ú±îÁö ¾ÆÇÁ´Ù. ¼Õ¸ñÀ» ±ÁÈ÷°í ÀÖÀ¸¸é ÅëÁõÀÌ ½ÉÇÏ´Ù. ¼Õ¸ñÀ» ¹Ýº¹ÀûÀ¸·Î »ç¿ëÇϴ ¿îÀüÀÚ, °¡Á¤ÁÖºÎ, ¾Ç±â ¿¬ÁÖÀÚ, °øÀå¶óÀÎÀÇ ±Ù·ÎÀÚ, ÄÄÇ»ÅÍ »ç¿ëÀÚ, ¸ñ¼ö°¡ ÇØ´çµÈ´Ù. ¼Õ¹Ù´Ú»À°¡ ±úÁö°Å³ª ³Ñ¾îÁö¸é¼­ ¼Õ¹Ù´ÚÀ¸·Î Â¤¾úÀ» ¶§µµ ¹ß»ýÇϸ砵幰°Ô Áøµ¿Çϴ °ø±¸¸¦ »ç¿ëÇØµµ ³ªÅ¸³ª±âµµ ÇÑ´Ù. ÀÓ»êºÎ, Åëdz, ·ù¸¶Æ¼½º °üÀý¿°, °©»ó»ù ±â´É ÀúÇÏÁõ, ´ç´¢º´ µîÀÌ ÀÖÀ» ¶§ ÀÌ·± Áõ»óÀÌ ¿Ã ¼ö ÀÖ´Ù. ¿©ÀÚ¿¡°Ô ´õ ¸¹°í ÁַΠÀÚÁÖ ¾²´Â ¼Õ¸ñÀÌ ÇØ´çµÈ´Ù. ½ÉÇÒ ¶§´Â ¼Õ¸ñ¿¡ ¶¥ÄḸÇÑ Å©±â·Î ºÎ¾î¿À¸¥´Ù. ´©¸£¸é ¾ÈÀ¸·Î ¾¦ µé¾î°¡±âµµ ÇÏ°í ´Ù½Ã ¿òÁ÷ÀÌ¸é Æ¢¾î³ª¿Â´Ù. ¼Õ¸ñ»À ¿©´ü °³ Áß¿¡ ¹Ý´Þ»À¶ó ºÒ¸®´Â ÀÛÀº»ÀÀÇ Àδ밡 À̿ϵǾý±ä´Ù. ÅëÁõÀ» °¨¼ÒÇϴ ġ·á·Î ºÎ¸ñ, ¾óÀ½ÂòÁú, ÀÌ´¢Á¦, Ç×»ýÁ¦¸¦ »ç¿ëÇϱ⵵ Çϸç ÅëÁõÀÌ °è¼ÓµÇ¸é ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å È£¸£¸óÀ» ¼Õ¸ñºÎ¿¡ ÁÖ»çÇÏ¿© ÅëÁõÀ» ÁÙÀδÙ. ºÎÀÛ¿ëÀ¸·Î´Â Àç¹ß·üÀÌ ³ô´Ù. 
¿µ¹® sudden infant death syndrome ÇÑ±Û ¿µ¾Æ±Þ»çÁõÈıº
¼³¸í   
  ÇÑ »ì ÀÌÇÏÀÇ °Ç°­ÇÑ ¾Æ±â°¡ ¾Æ¹«·± Á¶ÁüÀ̳ª ¿øÀΠ¾øÀÌ °©Àڱ⠻ç¸ÁÇßÀ» °æ¿ì¿¡ ³»¸®´Â Áø´ÜÀÌ´Ù. ÀÌ ÁõÈıºÀº »ýÈÄ 1~4°³¿ù »çÀÌ¿¡ °¡Àå ¸¹ÀÌ ¹ß»ýÇϸç, ´ëºÎºÐ ¹ã 10½Ã¿¡¼­ ¿ÀÀü 10½Ã »çÀÌ¿¡ ¹ß»ýÇÑ´Ù. Á¶»êÇϰųª ºÎ¸ð°¡ Èí¿¬ÀÚÀÏ °æ¿ì, 20¼¼ ÀÌÇÏ »ê¸ðÀÇ ÃÊ»ê, ÀÓ½ÅÀü °Ç°­°ü¸®¿¡ ¼ÒȦÇÑ »ê¸ð¿¡°Ô¼­ Å¾ ¿µ¾Æ¿¡°Ô¼­ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. ÀÌ ÁõÈıºÀ¸·Î »ç¸ÁÇÑ ¿µ¾ÆÀÇ ÇüÁ¦ÀÏ °æ¿ì ÀϹÝÀûÀΠ¿µ¾Æº¸´Ù °É¸± È®·üÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antitoxic immunity
    Ç×µ¶¼Ò¸é¿ª
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
  • athreptic immunity
    ¹«¿µ¾ç¸é¿ª
  • acquired immunity
    ÈÄõ¸é¿ª
  • active immunity
    ´Éµ¿¸é¿ª
  • adoptive immunity
    Â÷¿ë¸é¿ª, ÀÔ¾ç¸é¿ª
  • concomitant immunity
    ¼ö¹Ý¸é¿ª
  • cross immunity
    ±³Â÷¸é¿ª
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • gut immunity
    âÀڸ鿪, Àå°ü¸é¿ª
  • herd immunity
    ¹«¸®¸é¿ª
  • humoral immunity
    ü¾×¸é¿ª
  • immunity
    1. ¸é¿ª 2. ¸é¿ª¼º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hepatorenal syndrome
    °£ÄáÆÏÁõÈıº
  • irritable bowel syndrome
    °ú¹Î´ëÀåÁõÈıº
  • Kallmann syndrome
    Ä®¸¸ÁõÈıº
  • Klinefelter's syndrome
    Ŭ¶óÀÎÆçÅÍÁõÈıº
  • Korsakoff's syndrome
    ÄÚ¸£»çÄÚÇÁÁõÈıº
  • locked-in syndrome
    °¨±ÝÁõÈıº
  • Mallory-Weiss syndrome
    ¸»·Î¸®¹ÙÀ̽ºÁõÈıº
  • Marfan syndrome
    ¸¶¸£ÆÇÁõÈıº
  • myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • nephritic syndrome
    ÄáÆÏ¿°ÁõÈıº
  • nephrotic syndrome
    ÄáÆÏÁõÈıº, ½ÅÁõÈıº
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • overuse syndrome
    °úµµ»ç¿ëÁõÈıº
  • paraneoplastic syndrome
    ½Å»ý¹°µþ¸²ÁõÈıº
  • Parkinson's syndrome
    ÆÄŲ½¼ÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ceruloplasmin deficiency
    ¼¼·ê·ÎÇö󽺹ΰáÇÌ
  • complement deficiency
    µµ¿òü°áÇÌ
  • deficiency
    °áÇÌ(Áõ)
  • deficiency disease
    ¿µ¾ç°áÇ̺´
  • fat deficiency disease
    Áö¹æ°áÇÌÁõ
  • functional deficiency
    ±â´É°áÇÌ
  • histogenetic deficiency
    Á¶Á÷¹ß»ý°áÇÌ
  • immune deficiency
    (¢¡immunodeficiency) ¸é¿ª°áÇÌ
  • latent deficiency
    ÀáÀç°áÇÌÁõ
  • leukocyte adhesion deficiency
    ¹éÇ÷±¸ºÎÂø°áÇÌÁõ
  • mental deficiency
    Á¤½Å¹Ú¾à
  • milk dietary deficiency
    ¿ìÀ¯¿µ¾çÀå¾Ö
  • mineral deficiency
    ¹«±âÁú°áÇÌ(Áõ)
  • nutritional deficiency disease
    ¿µ¾ç°áÇ̺´
  • thyroid hormone deficiency
    ¹æÆÐ»ùÈ£¸£¸ó°áÇÌ, °©»ó»ùÈ£¸£¸ó°áÇÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunity, humoral
    ü¾×¼º¸é¿ª
  • immunity, innate
    ¼±Ãµ¸é¿ª
  • immunity, local
    ±¹¼Ò¸é¿ª
  • immunity, maternal
    ¸ð¼º¸é¿ª
  • immunity, native
    ¼±Ãµ¸é¿ª
  • immunity, nonspecific
    ºñƯÀ̸鿪
  • immunity, passive
    ¼öµ¿¸é¿ª
  • immunity, protective
    ¹æ¾î¸é¿ª
  • immunity, specific
    ƯÀ̸鿪
  • immunity, tissue
    Á¶Á÷¸é¿ª
  • immunity, transplantation
    À̽ĸ鿪
  • immunity,cell-mediated
    ¼¼Æ÷¸Å°³¼º(á¬øàØÚË¿àõ)
  • immunity,humoral
    ü¾×¼º
  • inborn immunity
    ¼±Ãµ(¼º) ¸é¿ª.
  • individual immunity
    °³Ã¼¸é¿ª.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cellular detection
    ¼¼Æ÷°ËÃâ
  • cellular granule
    ¼¼Æ÷°ú¸³
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
  • cellular hypersensitivity
    ¼¼Æ÷¼º°ú¹Î¹ÝÀÀ
  • cellular infiltration
    ¼¼Æ÷ħÀ±(¡­öÙëÈ).
  • cellular interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cellular invagination
    ¼¼Æ÷ÇÔÀÔ
  • cellular islands
    ¼¼Æ÷¼¶
  • cellular layer
    ¼¼Æ÷ÆÇ
  • cellular membrane
    ¼¼Æ÷¼º¸·
  • cellular nevus
    ¼¼Æ÷¼º¸ð¹Ý
  • cellular oncogene
    ¼¼Æ÷¾ÏÀ¯ÀüÀÚ
  • cellular oncogenes
    ¼¼Æ÷¼º Á¾¾çÀ¯ÀüÀÚ
  • cellular process
    ¼¼Æ÷µ¹±â
  • cellular protooncogenes
    ¼¼Æ÷¼º ¿øÁ¾¾çÀ¯ÀüÀÚ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Hormone deficiency
    È£¸£¸ó°áÇÌ
    [¿¾ ¿ë¾î] È£¸£¸ó°áÇÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • acquired immunity
    "ȹµæ¸é¿ª (üòÔðØóæ¹), ÈÄõ¸é¿ª (ý­ô¸Øóæ¹)"
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹)
  • adoptive immunity
    ¾çÀڸ鿪(å×í­Øóæ¹)
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • immunity
    ¸é¿ª(Øóæ¹)
  • inherited immunity
    À¯Àü¸é¿ª(ë¶îîØóæ¹)
  • innate immunity
    "ÀÚ¿¬¸é¿ª(í»æÔØóæ¹), ¼±Ãµ¸é¿ª(à»ô¸Øóæ¹)"
  • lysogenic immunity
    ¿ë¿ø¸é¿ª(éÁê«Øóæ¹)
  • native immunity
    ÀÚ¿¬¸é¿ª(í»æÔØóæ¹)
  • natural immunity
    ÀÚ¿¬¸é¿ª(í»æÔØóæ¹)
  • nonspecific immunity
    ºñƯÀÌ ¸é¿ª(Þª÷åì¶Øóæµ)
  • passive immunity
    ¼öµ¿¸é¿ª(áôÔÑØóæ¹)
  • protective immunity
    º¸È£ ¸é¿ª¼º(ÜÁûÞØóæ¹àõ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • superinfection immunity
    Áß°¨¿° ¸é¿ª (ñìÊïæøØóæ¹)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Marfan's syndrome
    ¸¶¸£ÆÎÁõÈıº
  • medial medullary syndrome
    ³»Ãø¿¬¼öÁõÈıº
  • Meniere's syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • middle lobe syndrome
    Áß¿±ÁõÈıº
  • mucocutaneous lymph node syndrome
    ÇǺÎÁ¡¸·¸²ÇÁÀýÁõÈıº
  • mucocutaneous ocular syndrome
    ÇǺÎÁ¡¸·¾ÈÁõÈıº
  • nephrotic syndrome
    ½ÅÁõÈıº, ³×ÇÁ·Î½Ã½ºÁõÈıº
  • omental adhesion syndrome
    ´ë¸Á¸·À¯ÂøÁõÈıº
  • overlap syndrome
    ÁßøÁõÈıº
  • Pancoast syndrome
    ÆÇÄÚ½ºÆ® ½Åµå·Ò
  • parietooccipital syndrome
    µÎÁ¤¿±Èĵο±ÁõÈıº
  • peutz-Jegher's syndrome
    Æ÷ÀÌÃ÷-¿¹°ÅÁõÈıº
  • PIE syndrome
    È£»ê±¸¼ºÆóħ½ÀÁõÈıº
  • Poland syndrome
    Æú¶õµåÁõÈıº
  • posterior interosseous syndrome
    Èİñ°£ÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IGD idiopathic growth hormone deficiency; interglobal distance; isolated gonadotropin deficiency
MCD magnetic circular dichroism; mast-cell degranulation; mean cell diameter; mean of consecutive differ...
ADS acute death syndrome; acute diarrheal syndrome; Alcohol Dependence Scale; alternative delivery syste...
IAS immunosuppressive acidic substance; infant apnea syndrome; insulin autoimmune syndrome; interatrial ...
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
cFN Cellular FN
CRABP Cellular RA binding protein
CRBP Cellular Retinol-Binding Protein
c-SRC Cellular SRC
CAM Cellular adhesion molecules
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cellular blue nevus
    ¼¼Æ÷¼º û»ö ¸ð¹Ý
    û»ö ¸ð¹ÝÀÇ Æ¯ÀÌÇÑ º¯ÇüÀ¸·Î¼­ ÀÓ»óÀû ¹× Á¶Á÷ÇÐÀûÀ¸·Î ¾Ç¼º Èæ»öÁ¾À¸·Î ¿ÀÀεDZ⠽±´Ù. À̰ÍÀº µÐºÎ¿Í õ¹Ì°ñ ºÎÀ§¿¡ È£¹ßÇϸç Ä¿´Ù¶õ û»ö ¶Ç´Â Èæ»öÀÇ ´Ü´ÜÇÑ °áÀý·Î ³ªÅ¸³­´Ù.
  • cellular cementum
    ¼¼Æ÷¼º ¹é¾ÇÁú
    Ä¡¾ÆÀÇ Ä¡±Ù¸éÀ» µ¤°í ÀÖ´Â ¼®È¸È­µÈ ¹°ÁúÀÇ ºÎºÐ. °ñ°ú ºñ½ÁÇÏ¸ç ¹é¾Ç ¼¼Æ÷°¡ ¼Ò¿Í³»¿¡¼­ ¹¯Çô ÀÖ´Ù. ¶ÇÇÑ, ¹é¾ÇÁúÀÇ ¼¼°üÀ» µû¶ó ¿øÇüÁú µ¹±â°¡ »¸¾î ÀÖ°í ÀÌ´Â ÀÎÁ¢ÇÑ ¼Ò¿ÍÀÇ ¼¼°ü°ú ¹®ÇÕÇÑ´Ù. ¼Ò¿Í´Â ÃþÆÇÇüÀ¸·Î Á¤·ÄÇÏ¿© ¼®È¸Áú¿¡ »êÀçÇØ ÀÖ´Ù. ¼¼Æ÷¼º ¹é¾ÇÁúÀº ÁÖ·Î Ä¡±ÙÀÇ Ä¡±Ù´Ü ºÎºÐ¿¡ ±¹¼ÒÈ­µÇ¾î Àִµ¥ ¹«¼¼Æ÷¼º ¹é¾ÇÁú À§¿¡ Ä§ÂøµÉ ¼öµµ ÀÖ°í, ¹é¾ÇÁú Èí¼ö ºÎÀ§¿¡¼­ Ä¡À¯ ÀÛ¿ëÀ» ÇÏÁö ¸øÇÒ ¼öµµ ÀÖ´Ù.
  • cellular connective tissue
    ¼¼Æ÷¼º °áÇÕ Á¶Á÷
    ¼¼Æ÷·Î »çÀ̰¡ ¿¬°áµÇ¾î ÀÖ´Â Á¶Á÷.
  • cellular detection
    ¼¼Æ÷ °ËÃâ
    ¼¼Æ÷ÀÇ Á¸À縦 °ËÃâÇÏ´Â °Í.
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
    ¼¼Æ÷¿¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯È­ÇÑ »óÅÂ.
  • cellular infiltration
    ¼¼Æ÷ ħÀ±
    ¼¼Æ÷°¡ ħÀ±¿¡ ÀÇÇÏ¿© Ä§ÂøµÈ °Í.
  • cellular invagination
    ¼¼Æ÷ ÇÔÀÔ
    ¼¼Æ÷ÀÇ ¾î¶² ºÎºÐÀÌ ´Ù¸¥ ºÎºÐ³»¿¡ ÇÔÀÔÇÏ´Â °Í.
  • cellular layer
    ¼¼Æ÷ Ãþ
    ¼¼Æ÷°¡ °ÅÀÇ ÀÏÁ¤ÇÑ µÎ²²ÀÇ, ȬÀ̺Ҹð¾çÀÇ Á¶Á÷ ±¸Á¶¸¦ °¡Áö´Â °Í.
  • cellular membrane
    ¼¼Æ÷¼º ¸·
    ¼¼Æ÷ÀÇ Ç¥¸éÀ» µ¤°Å³ª °øµ¿ÀÇ ³»¸éÀ» µ¤´Â, ¶Ç´Â °ø°£À̳ª ±â°üÀ» ³ª´©´Â ¾ãÀº ÃþÀÇ Á¶Á÷.
  • cellular oncogene
    ¼¼Æ÷ ¾Ï À¯ÀüÀÚ
    ¼¼Æ÷ÀÇ ¿øÀο¡ ÀÇÇØ¼­ Á¾¾çÇü¼ºÀ» ÀÏÀ¸Å°´Â À¯ÀüÀÚ.
  • cellular pole
    ¼¼Æ÷ ±Ø
    ¼¼Æ÷ÀÇ ÃàÀÇ ¾î´À ÇÑÂÊ ³¡ºÎºÐ. ¼¼Æ÷ÀÇ »ó¹ÝµÈ ºÐ¸®ÇÐÀû ¼ºÁúÀ» °¡ Áø µÎ Á¡ ÁßÀÇ Çϳª.
  • cellular proliferative layer
    ¼¼Æ÷¼º Áõ½ÄÃþ
    ¼¼Æ÷ÀÇ µ¿ÀÏÇüÅÂÀÇ Àç»ý»ê ¶Ç´Â Áõ½ÄÃþ.
  • cellular radiobiology
    ¼¼Æ÷ ¹æ»ç¼± »ý¹°ÇÐ
    ±¤¼±, Àڿܼ±, Àü¸®¹æ»ç¼±ÀÇ Á¶Á÷, ¼¼Æ÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¿¬±¸´ë»óÀ¸·Î ÇÑ °úÇÐÀÇ ÇÑ ºÐ¾ß.
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • cellular sensitivity
    ¼¼Æ÷ °¨¼ö¼º
    ¼¼Æ÷°¡ °¨¼ö¼ºÀÌ ÀÖ´Â »óÅ ¶Ç´Â ¼ºÁú·Î¼­, Àڱؿ¡ ´ëÇØ¼­ ºñÁ¤»óÀûÀ¸·Î ¹ÝÀÀÇϰųª ¶Ç´Â ºü¸£°í ¿¹¹ÎÇÏ°Ô ¹ÝÀÀÇÏ´Â »óŸ¦ ³ªÅ¸³»´Â µ¥ Á¾Á¾ »ç¿ëµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
17-hydroxylase deficiency syndrome <syndrome> Congenital deficiency of adrenocortical, and possibly ovarian, steroid C-17a hydroxylase; the resulting excessive secretion of corticosterone and deoxycorticosterone produces hypertension and hypokalaemic alkalosis; absence of aldosterone secretion in such patients may indicate a multiple enzymic deficiency.
(05 Mar 2000)
leukocyte-adhesion deficiency syndrome <syndrome> Rare, autosomal recessive disorder caused by deficiency of the beta 2 integrin receptors (receptors, leukocyte-adhesion) comprising the CD11/CD18 family of glycoproteins. The syndrome is characterised by abnormal adhesion-dependent functions, especially defective tissue emigration of neutrophils, leading to recurrent infection.
(12 Dec 1998)
acquired immunity <immunology> A form of cellular defense which identifies certain foreign substances (antigens) as harmful to the body. For this reason, the body can acquire resistance to a particular foreign agent.
These foreign agents are then attacked by sensitised T lymphocytes (cellular immunity). White blood cells, plasma cells, B lymphocytes and other specialised immune system cells act in concert with T lymphocytes to produce antibodies (humoral immunity) that attach to the antigen directing T-cells to attack.
Antibodies also stimulate the release of special chemical mediators in the blood (for example complement, interferon) that further enhance antigen destruction.
(13 Nov 1997)
active immunity <immunology> An organisms resistance to disease or infection, developed because the organisms immune system has produced antibodies after an infection or innoculation.
(06 May 1997)
adoptive immunity <immunology> Immunity to disease or infection conferred on a previously non-immune individual by transferring lymphocytes from a previously immune individual to the non-immune individual.
(15 Jan 1998)
allograft immunity <immunology> The recipient's immune system rejects tissue grafted from a genetically dissimilar donor (of the same species) and stages an immune attack against it.
(09 Oct 1997)
antiviral immunity Immunity resulting from virus infection, either naturally acquired or produced by intentional vaccination; compared to some bacterial immunity's, it is of relatively long duration, but this may be the result of infection-immunity rather than being peculiar to virus infection per se, since it occurs also in bacterial immunity after infections such as typhoid fever.
(05 Mar 2000)
artificial active immunity See: acquired immunity.
(05 Mar 2000)
artificial passive immunity See: acquired immunity.
(05 Mar 2000)
bacteriophage immunity The state induced in a bacterium by lysogenization, the lysogenic bacterium being insusceptible to further lysogenization or to a lytic cycle by a superinfecting bacteriophage, in contradistinction to bacteriophage resistance.
(05 Mar 2000)
general immunity Immunity associated with widely diffused mechanisms that tend to protect the body as a whole, as compared with local immunity.
(05 Mar 2000)
maternal immunity <epidemiology> Immunity for a neonate provided by IgG antibody generated by a mother and passed across the placenta to the unborn offspring. This provides short lived protection (with a typical half life of 3-6 months) to the neonate. Also known as immunity.
(05 Dec 1998)
passive immunity <immunology> Immunity acquired by the transfer from another animal of antibody or sensitised lymphocytes. Passive transfer of antibody from mother to offspring is important for immune defense during the perinatal period.
(18 Nov 1997)
relative immunity A modified, not completely effective resistance that results when there is a sort of "fluctuating equilibrium" between the defense mechanisms of the host and the infective agent.
(05 Mar 2000)
cell-mediated immunity <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody.
Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites.
(26 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á